00 / pharma& news
pharma& is happy to announce that a share purchase agreement with Zatortia Holdings Ltd., Limassol, Cyprus (subsidiary of Shilpa Medicare Ltd., India) has been entered to acquire 100% of shares of LOBA Feinchemie GmbH, Fischamend, Austria.
This acquisition enables pharma& to vertically integrate a high-quality Active Pharmaceuticals Ingredient producer in order to secure long-term supply of its highly niche specialty care medicines. LOBA renews its firm commitment to the development and production of high quality Intermediates, Fine Chemicals and Active Pharmaceutical Ingredients and is looking forward to build upon the trusted and long-lasting customer relationships having been established in the past.
Continuing to build up our organisation, following the acquisition of Pegasys, pharma& is pleased to welcome Detlef Jakschies, PhD as Medical & Scientific Director. Detlef will be responsible for leading and implementing pharma&’s medical and scientific strategies, developing customized solutions to best serve the patients’ needs, with a focus on our worldwide business for Pegasys (Peginterferon alfa 2a).
Detlef joins us with a strong background in the field of Interferons, ranging from research at the Medical School of Hannover to various commercial roles in the pharmaceutical industry over the last 20 years, focussing on scientific leadership in the field of haematology and oncology. Respected and valued for his deep scientific understanding and clinical know-how, he is regarded as a valuable partner for his customers and peers alike and has established a strong network within the scientific community.
We are proud to announce that we recently signed an agreement
with F. Hoffmann-La Roche Ltd to acquire the worldwide rights of
Pegasys (Peginterferon alfa 2a) excl. China and Japan,
securing long-term access and supply for patients benefiting
from this well established therapy option.
For any inquiries please contact us at